Liver extract-folic acid-cyanocobalamin vs placebo for chronic fatigue syndrome.
Kaslow, J E, Rucker, L, Onishi, R · Archives of internal medicine · 1989
Quick Summary
Researchers tested a liver extract injection containing folic acid and B12 (a treatment some doctors in Southern California were recommending for ME/CFS) against a placebo injection in 15 ME/CFS patients. Both the real treatment and placebo improved patients' symptoms and function, but there was no meaningful difference between the two groups. The strong response to placebo suggests that patients' expectations and other non-chemical factors may play a significant role in how they experience symptom improvement.
Why It Matters
This study demonstrates the critical importance of placebo-controlled trials in ME/CFS research, as patients can show substantial improvement from non-specific factors alone. Understanding this placebo phenomenon helps patients and clinicians distinguish between treatments with true biological effects and those that appear helpful due to expectation, and guides future research design to more accurately identify effective therapies.
Observed Findings
Both LEFAC and placebo produced improvements in multiple functional status measures in the 15 study participants.
No statistically significant difference in response rates was detected between the active treatment and placebo groups.
A notably strong placebo response was observed across the cohort.
Patients showed measurable functional improvements by several criteria despite group assignment.
Inferred Conclusions
LEFAC does not demonstrate efficacy beyond placebo effect for ME/CFS in this population.
The strong placebo response suggests that non-specific factors significantly influence symptom reporting and functional status in CFS patients.
Routine use of LEFAC injections for CFS is not supported by evidence from this controlled trial.
Remaining Questions
Does LEFAC provide benefit in larger or more diverse patient populations, or in specific ME/CFS subgroups?
What mechanisms drive the strong placebo response observed, and can they be leveraged therapeutically while maintaining scientific rigor?
Are there any biological markers or characteristics that predict which patients might respond to LEFAC or placebo?
What This Study Does Not Prove
This study does not prove that LEFAC is completely ineffective for all patients or mechanisms—only that in this small trial, it did not demonstrate superiority over placebo. It also does not clarify which components (if any) of the liver extract might have biological activity, nor does it establish whether different patient subgroups might respond differently. The strong placebo response does not mean symptom improvements are 'not real,' but rather reflects the complexity of how the mind and body interact in symptom perception.
Tags
Symptom:Fatigue
Method Flag:PEM Not DefinedWeak Case DefinitionSmall Sample